Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling

BACKGROUND: Osteosarcoma, ranking as the second primary cause of cancer-related death, is the most common type of bone cancer. Doxorubicin (DOX) is used as a first-line treatment for osteosarcoma; however, the tumour recurrence rate remains high. Recent studies have suggested that DOX-induced migrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Zhi C., Wang, Jia Q., Ge, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Speaking Orthopaedic Society 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231956/
https://www.ncbi.nlm.nih.gov/pubmed/32440509
http://dx.doi.org/10.1016/j.jot.2019.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231956/
https://www.ncbi.nlm.nih.gov/pubmed/32440509
http://dx.doi.org/10.1016/j.jot.2019.07.003

Ejemplares similares